We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, EMA Collaborate on Model for Developing Rare Pediatric Drugs
FDA, EMA Collaborate on Model for Developing Rare Pediatric Drugs
The FDA and the European Medicines Agency released a draft joint plan to support the development of pediatric treatments for Gaucher disease — an approach the agencies say can apply to rare diseases in general.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor